CLINICAL TRIALS PROFILE FOR OMNIPRED

All Clinical Trials for OMNIPRED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00782717 ↗	A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients	Completed	Alcon Research	Phase 2	2008-11-01	The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
NCT02229136 ↗	Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus	Active, not recruiting	Novartis Pharmaceuticals	Phase 2	2014-09-04	This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis (mouth sores) in postmenopausal patients undergoing treatment with an aromatase inhibitor plus everolimus. An exploratory analysis will also evaluate patient response to next anti-cancer therapy of physician's choice following discontinuation of therapy with an aromatase inhibitor plus everolimus.
NCT02229136 ↗	Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus	Active, not recruiting	US Oncology Research	Phase 2	2014-09-04	This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis (mouth sores) in postmenopausal patients undergoing treatment with an aromatase inhibitor plus everolimus. An exploratory analysis will also evaluate patient response to next anti-cancer therapy of physician's choice following discontinuation of therapy with an aromatase inhibitor plus everolimus.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Stanford University	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	University of California, San Francisco	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Oregon Health and Science University	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.

Clinical Trial Conditions for OMNIPRED

Condition Name

Condition Name for OMNIPRED
Intervention	Trials
Oral Mucositis	1
Stomatitis	1
Transplantation, Cornea	1
Transplantation, Corneal	1

Condition MeSH

Condition MeSH for OMNIPRED
Intervention	Trials
Macular Edema	1
Diabetic Retinopathy	1
Stomatitis	1
Cataract	1

Clinical Trial Locations for OMNIPRED

Trials by Country

Trials by Country for OMNIPRED
Location	Trials
United States	3

Trials by US State

Trials by US State for OMNIPRED
Location	Trials
Oregon	1
California	1
Texas	1

Clinical Trial Progress for OMNIPRED

Clinical Trial Phase

Clinical Trial Phase for OMNIPRED
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for OMNIPRED
Clinical Trial Phase	Trials
Active, not recruiting	2
Completed	1

Clinical Trial Sponsors for OMNIPRED

Sponsor Name

Sponsor Name for OMNIPRED
Sponsor	Trials
Alcon Research	1
Novartis Pharmaceuticals	1
US Oncology Research	1

Sponsor Type

Sponsor Type for OMNIPRED
Sponsor	Trials
Other	4
Industry	3

Last updated: May 4, 2026

OMNIPRED: Clinical Trial Update, Market Analysis, and Projection

No complete, verifiable clinical-trial record, regulatory status, or market data is available for the drug name “OMNIPRED” from the information in this request. Without authenticated identifiers (e.g., INN/generic name, manufacturer, salt/formulation, or a regulatory application number), any clinical update, competitive positioning, or revenue projection would be non-factual.

What is OMNIPRED (generic, salt/formulation, sponsor) and what stage is it in?

No validated source-linked dossier is provided for “OMNIPRED,” so trial phase, enrollment status, primary endpoints, and timelines cannot be stated.

What clinical trial updates can be reported?

No trial identifiers are provided (NCT/EudraCT/CT.gov entries, protocol numbers, or published results), so recruitment status, readouts, safety findings, or comparator arms cannot be confirmed.

What market analysis can be produced (size, segment, pricing, share drivers)?

No evidence-linked inputs are provided that connect “OMNIPRED” to a specific active ingredient, indication, route, or strength. Market sizing requires indication mapping, patient population definition, and pricing benchmarks by geography and setting, none of which can be tied to “OMNIPRED” from this request.

What revenue and adoption projections are supportable?

Any projection model depends on (1) confirmed indication(s), (2) clinical efficacy and safety, (3) label scope and dosing regimen, (4) payer/coverage dynamics, and (5) competitive set. None are available for “OMNIPRED” from the information provided.

---

Key Takeaways

• “OMNIPRED” cannot be mapped to a specific drug identity (active ingredient and formulation) with the information in this request.
• Clinical trial phase, timelines, and readouts cannot be reported without validated trial identifiers.
• Market sizing, competitive positioning, and revenue projections cannot be grounded in verifiable indication and product-level facts.

FAQs

1. What does “OMNIPRED” refer to?
   The request does not include the generic name, salt/formulation, sponsor, or regulatory identifiers needed to map it to a specific medicinal product.

2. Which clinical trials exist for OMNIPRED?
   No NCT/EudraCT/protocol identifiers or published study links are provided, so trials cannot be enumerated.

3. What indication is OMNIPRED targeting?
   The request does not specify the therapeutic area or approved/under-development indications.

4. How would market projections be calculated if OMNIPRED were identified?
   Projections would be modeled from indication-linked epidemiology, expected uptake curves, pricing and reimbursement, and competitive share based on confirmed label and clinical outcomes.

5. Can you estimate revenue without pricing and label scope?
   Not in a factual way; revenue forecasts require confirmed dose regimen, treatment duration, and payer coverage assumptions tied to the actual active ingredient and indication.

---

References

[1] No cited sources were available or provided in the request for “OMNIPRED.”